title: Adjuvant therapy for renal cell carcinoma.
abstract: In the past few years, several targeted therapies have been approved by the U.S. Food and Drug Administration for the treatment of advanced renal cell carcinoma. This has led to an improvement in the progression-free survival and quality of life for these patients. Nevertheless, the use of these and other therapies in the adjuvant setting has failed to demonstrate a clear benefit. Immune therapies and hormonal or targeted therapies have been studied in this indication, and there are clinical trials currently enrolling patients with high risk of relapse. This article reviews the available data and the ongoing trials exploring the role of adjuvant therapy for kidney cancer.
authors.affiliation: Medical Oncology Department, University Hospital La Paz - IdiPAZ, Madrid, Spain. Electronic address: alvaropintomarin@gmail.com.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Pinto
mesh_terms: D002292:Carcinoma, Renal Cell / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant / Q000379:methods; D003131:Combined Modality Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007680:Kidney Neoplasms / Q000628:therapy*
keywords: Clinical trials; Immune therapy; Relapse risk; Risk reduction; Targeted therapy